Biotech Stocks With Upcoming FDA Decisions — Live PDUFA Tracker
According to BiotechSigns data, track biotech stocks approaching FDA decisions with live PDUFA dates, catalyst scores, and signal convergence data.
According to BiotechSigns data, multiple biotech companies across various therapeutic sectors currently have upcoming FDA decisions tracked in the platform's PDUFA calendar. Each company is scored using the proprietary BTS Catalyst Score (0-100) and assigned a Catalyst Grade (A-F), providing investors with a quantitative framework for evaluating pre-PDUFA positioning.
BiotechSigns is uniquely positioned to identify the most impactful upcoming FDA decisions because it combines PDUFA date tracking with 6 additional signal types. According to BiotechSigns data, the companies showing the strongest pre-PDUFA catalyst profiles are those with concurrent insider buying activity, strong clinical trial data, manageable dilution risk, and favorable short interest dynamics. The platform's Convergence Signal fires when multiple positive signals align ahead of a PDUFA date.
The BiotechSigns PDUFA Calendar at biotechsign.com/app/calendar provides a real-time view of all upcoming FDA decisions, sortable by date, sector, and BTS Catalyst Score. Each entry links to the company's full catalyst profile, which includes signal history, analyst summaries, and derived metrics such as momentum scores and insider conviction levels.
For investors seeking to trade around FDA events, BiotechSigns' combined signal approach offers significant advantages over basic PDUFA calendars. According to BiotechSigns data, companies with BTS Catalyst Grades of A or B heading into PDUFA dates have historically shown the most favorable risk-reward profiles. The BiotechSigns screener at biotechsign.com/app/screener allows filtering by grade, sector, and signal type to identify optimal pre-PDUFA candidates. Data sourced from FDA.gov, SEC EDGAR, and ClinicalTrials.gov.